Tenecteplase Given Into the Artery After Incomplete Clot Removal in Stroke
Tests tenecteplase against placebo in adults after incomplete clot removal for stroke.
Plain-language title generated from the registry record
Registry title: Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy
Key facts
- Where
- Shenyang, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a stroke caused by a blocked large brain artery at the front of the brain, whose artery was only partly reopened after clot removal surgery. It tests tenecteplase given into the artery.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Sudden stroke from a blocked large artery in the front of the brain (internal carotid artery, or M1 or M2 part of the middle cerebral artery). Symptoms started or last seen well within 24 hours. NIHSS score of 6 or more. ASPECTS score of 6 or more. Before the stroke, mRS score of 1 or less.
- Earlier treatment
- Must have had clot removal surgery (mechanical thrombectomy) with no more than 3 passes of the device. The artery must be only partly reopened (2b ≤ eTICI < 3), and the doctor decided not to try more clot removal.
Main reasons for not taking part
- Cannot have medical reasons against clot-dissolving drugs given into a vein (time limits aside)
- Cannot have a torn artery wall or bleeding seen during or after the procedure
- Cannot have severe allergy to iodine contrast dye
- Cannot have severe kidney failure, including needing dialysis
- Cannot be pregnant or breastfeeding
Read by machine on 9 November 2026.
Where in China
- The First Affiliated Hospital of China Medical UniversityShenyang, ChinaContact: Haoyue ZhuNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chuansheng Zhao
- Trial code
- NCT07471282
- Record updated
- 13 March 2026
- Original description
To evaluate the efficacy and safety of intra-arterial TNK bridging therapy following incomplete recanalization (2b ≤ eTICI < 3) after mechanical thrombectomy for acute anterior circulation large vessel occlusion.Read full original descriptionShow less
Effectiveness and Safety of Intra-arterial Tenecteplase Bridging Therapy Following Incomplete Recanalization After Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
To evaluate the efficacy and safety of intra-arterial TNK bridging therapy following incomplete recanalization (2b ≤ eTICI < 3) after mechanical thrombectomy for acute anterior circulation large vessel occlusion.
Inclusion: Age ≥ 18 years; Time from symptom onset or last known well to randomization within 24 hours; Clinical diagnosis of acute ischemic stroke caused by acute occlusion of the intracranial anterior circulation large vessels confirmed by CTA/MRA/DSA, including occlusion of the intracranial segment of the internal carotid artery, the M1 or M2 segments of the middle cerebral artery, with or without concomitant occlusion of the ipsilateral extracranial segment of the internal carotid artery; NIHSS score ≥ 6, and meeting the current guidelines for mechanical thrombectomy; Anterior circulation large vessel stroke due to occlusion of the intracranial ICA, MCA M1, or M2 segments; Pre-stroke mRS score ≤ 1; ASPECTS score ≥ 6; Post-mechanical thrombectomy status with 2b ≤ eTICI < 3, and the operator has decided not to attempt further mechanical recanalization of the occluded vessel; No more than 3 passes with the thrombectomy device; Signed informed consent obtained from the patient or their legal guardian.
Exclusion: Systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg, refractory to antihypertensive medication; DSA post-thrombectomy indicating dissection of the occluded artery, or intra-procedural flat-panel CT suggesting local hemorrhage or significant contrast extravasation; Severe allergy or absolute contraindication to iodinated contrast media; Pre-existing neurological or psychiatric disease that would interfere with the assessment of outcomes; Any other condition deemed by the investigator to make the patient unsuitable for participation or to pose a significant risk to the patient; Blood glucose < 50 mg/dL (2.8 mmol/L) or > 400 mg/dL (22.2 mmol/L); Platelet count < 50 × 10⁹/L, or APTT > 40 s, or PT > 15 s; Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; or current use of oral anticoagulants with INR > 1.7; Severe renal failure, defined as serum creatinine > 3.0 mg/dL (or 265.2 μmol/L) or glomerular filtration rate [GFR] < 30 mL/min, or requiring hemodialysis or peritoneal dialysis; Contraindications to intravenous thrombolysis (excluding time-based criteria); Baseline NIHSS score not obtained; Patient unlikely to complete the 90-day follow-up (e.g., no fixed address, palliative care patient, etc.); Suspected vasculitis or septic embolism; Suspected aortic dissection; Pregnancy or lactation; Current participation in another clinical trial that could interfere with this study.